Loading
A phase 3 trial of Ivonescimab, Paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Akeso, now recruiting.
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT06767527 by Akeso, with 416 participants planned, started 2025-02-07 and due to reach its primary completion in 2026-12. Interventions recorded: AK112, Nab-paclitaxel, Placebo. Conditions listed: Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Ivonescimab, Paclitaxel / nab-paclitaxel.
Shares Akeso, Ivonescimab, Paclitaxel / nab-paclitaxel.
Shares Akeso, Ivonescimab.
Shares Akeso, Ivonescimab.
Shares Akeso, Ivonescimab.
Shares Akeso, Ivonescimab.
Shares Akeso, Ivonescimab.
Shares Akeso, Ivonescimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/